SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is surging as investors pivot to energy plays due to a major supply disruption at Qatar's LNG facilities, fueling a potential short squeeze on its low-float ordinary shares. The community is heavily focused on the company's strategic position in European energy security, with intense discussion surrounding its recent reserve volume increases and the broader geopolitical instability impacting gas prices.

This first memecoin ever created completely by AI.

Turbo Toad Token

Turbo Toad Token ($TURBO) is generating intense community buzz as investors capitalize on its status as a prominent AI-generated meme coin with high trading volume. The community is actively debating its technical setup, closely monitoring resistance levels, and expressing strong conviction in a potential rally toward the penny mark as they anticipate broader market momentum.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently drawing intense community focus due to a combination of legal setbacks involving fraud allegations and broader market volatility that has triggered significant selling pressure. Investors are actively debating the company's valuation, questioning the feasibility of its ambitious AI and robotics initiatives, and reacting to widespread concerns over the current economic and geopolitical environment.

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic Plc

Medtronic is trending as investors digest a fiscal third-quarter earnings report that featured a revenue miss and subsequent stock price decline, leading to an increase in bargain-hunting activity among market participants. The community is actively debating the company's long-term value as a dividend aristocrat versus the immediate impact of its current financial performance and broader sector-wide pressure on medical device stocks.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors weigh aggressive M&A expansion plans led by CEO Brad Jacobs against recent volatility, with community debate centered on whether to treat current price weakness as a long-term accumulation opportunity or a signal of overvaluation. The stock remains a focal point for discussion around its role in the building materials sector, with participants closely monitoring for the next acquisition announcement to provide renewed momentum.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies is attracting investor attention as its recent Variperm acquisition and deleveraging efforts signal a shift toward stronger free cash flow and potential share repurchases. The community is actively discussing the stock's valuation disconnect and its positioning as a key beneficiary of resilient international activity and rebounding natural gas drilling demand.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently a focal point for investors following strong quarterly earnings, reaffirmed multi-hundred percent revenue growth guidance, and the successful securing of significant defense contracts for missile propulsion and autonomous swarm technology. Community discussion is heavily divided between retail investors capitalizing on the stock's high short interest for a potential squeeze and those focused on the long-term potential of the firm's pivot into integrated defense manufacturing.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is experiencing significant volatility as the market reacts to intense geopolitical instability in the Middle East, specifically regarding energy infrastructure and the potential closure of the Strait of Hormuz. Community discussion is sharply divided between bulls betting on a massive supply-driven price spike due to infrastructure damage, and bears highlighting the leveraged decay inherent in the product alongside bearish seasonal demand factors.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is trending following its recent NYSE listing, sparking intense debate among investors over its valuation relative to NAV and the impact of a six-month lock-up period on the tradable float. Community members are actively discussing whether the fund's high-profile AI and tech holdings justify the current premium or if the volatility is primarily driven by speculative trading and limited share availability.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing significant community attention as investors debate its potential for a major breakout, with many highlighting its resilience and year-to-date performance relative to other leading cryptocurrencies. The sentiment remains polarized, with bullish traders pointing toward upcoming network upgrades and whale accumulation, while skeptics express frustration over stagnant price action and compare the asset to other market alternatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Humacyte (HUMA) Projected to Post Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMA) will be releasing its Q4 2025 earnings before the market opens on Friday, March 27. (View Earnings Report at...

<ul class="summary-bullets"><li>Humacyte is looking to sell 25 million shares in order to raise $20 million.</li><li>The company said it plans to use the proceeds to support the commercialization of Symvess for vascular trauma.</li><li>Humacyte also agreed not to pursue other commercialization negotiations in Saudi Arabia until July 2026.</li></ul>Shares of Humacyte, Inc. (HUMA) tanked more than 20% to an all-time low on Thursday, after the company announced a $20 million fundraising at a significant discount to the stock’s closing price a day earlier.Simultaneously, the company also announced a $1.5 million minimum purchase commitment from Saudi Arabia for its&nbsp;Symvess, a bioengineered, off-the-shelf human blood vessel.Humacyte signed a new securities purchase agreement with several new institutional investors to sell 25 million shares of common stock in a registered direct offering. The deal is expected to generate gross proceeds of about $20 million and is slated to close around March 20, 2026. This translates to $0.80 per share, a 25% discount to the stock’s Wednesday closing price of $1.06.The company added that it plans to use the proceeds to support the commercialization of Symvess for vascular trauma, advance a Biologics License Application (BLA) supplement for hemodialysis use, and fund ongoing clinical and pipeline development programs.<h2 class="st-heading-2">Humacyte Is In Talks To Form JV In Saudi Arabia</h2>Humacyte said the order will support a clinical evaluation and outreach program in hospitals across Saudi Arabia. The company is also in talks to form a joint venture and secure commercialization rights for Symvess in the country.Humacyte will train local medical professionals to use the product and has agreed not to pursue any other commercialization negotiations in Saudi Arabia until July 2026. While Symvess is FDA-approved for the treatment of extremity vascular trauma, other uses remain investigational.“The clinical evaluation and outreach program is designed to build awareness and understanding of the Symvess technology among healthcare providers as we pursue regulatory approval and prepare for potential commercial launch in the KSA,” said Laura Niklason, Founder and CEO of Humacyte.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.One user believes <a href="https://stocktwits.com/symbol/HUMA">HUMA</a> is a “great candidate” for a reverse stock split.<stembedurl>https://stocktwits.com/Morslan/message/647964164</stembedurl>Another user expects the stock to fall to $0.3. It is currently trading around $0.8.<stembedurl>https://stocktwits.com/paulN98/message/647972889</stembedurl>Year-to-date, the stock has declined around 10%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-rivn-stock-jump-in-pre-market-today/cZ3aSSTRIhb">Uber Expands Autonomous Vehicle Push - Here’s Everything To Know About Its Partnership With Rivian</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stocks chart. (Image Courtesy: Getty Images)

Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today?

The company said it is in talks to form a joint venture and secure commercialization rights for Symvess, a bioengineered blood vessel, in Saudi Arabia.

Equity

Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday...

Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional...

D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Thursday...

Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One...

Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close.

Humacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a research note on Monday...

<ul class="summary-bullets"><li>The National Defense Authorization Act for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies to fix severe artery injuries in arms and legs.</li><li>This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.</li><li>Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.</li></ul>Humacyte Inc. (HUMA) on Monday announced that the recently adopted FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels.The company stated that the DOD funding is intended to support the evaluation and incorporation of biologic vascular repair technologies for warfighters with traumatic vascular injuries.Humacyte stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).<a href="https://stocktwits.com/symbol/HUMA">Humacyte shares</a> were up more than 30% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Does The NDAA Say?</h2>The National Defense Authorization Act (NDAA) for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies&nbsp;to fix severe artery injuries in arms and legs.This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.Autologous vein harvesting refers to the surgical removal of the patient’s own healthy vein, which is usually the great saphenous vein (GSV) in the leg. This is used as a graft, typically in coronary artery bypass grafting (CABG) or peripheral vascular surgery.“This historic, first-of-its-kind federal investment will help ensure our soldiers continue to have access to cutting-edge treatments and state-of-the-art care whenever and wherever they need it,” said Humacyte founder and CEO, Laura Niklason.<h2 class="st-heading-2">What Is Humacyte’s Symvess?</h2>Symvess is a human-derived biologic vessel&nbsp;used when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible.The company says Symvess is off-the-shelf and ready to use, with no immune response observed to date. It also states that Symvess has low susceptibility to infection.Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.<a href="https://stocktwits.com/symbol/HUMA">HUMA stock</a> is up 26% year-to-date, but down 71% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.13	--	--	N/A
Q3 '25	-$0.15	-$0.11	27.17%	BEAT
Q2 '25	-$0.16	-$0.24	-48.35%	MISSED
Q1 '25	-$0.19	$0.28	246.83%	BEAT
Q4 '24	-$0.25	-$0.16	37.25%	BEAT

HUMA
Humacyte Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest HUMA News

HUMAHumacyte Inc